世界卫生组织关于妊娠、分娩和妊娠期疾病管理的建议

WHO recommendations on themanagement of sickle-cell diseaseduring pregnancy, childbirth andthe interpregnancy period WHO recommendations on the management of sickle cell disease during pregnancy, childbirth and theinterpregnancy period ISBN 978-92-4-010912-4 (electronic version)ISBN 978-92-4-010913-1 (print version) © World Health Organization 2025 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO;https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercialpurposes, provided the work is appropriately cited, as indicated below. In any use of this work, thereshould be no suggestion that WHO endorses any specific organization, products or services. The use ofthe WHO logo is not permitted. If you adapt the work, then you must license your work under the sameor equivalent Creative Commons licence. If you create a translation of this work, you should add thefollowing disclaimer along with the suggested citation: “This translation was not created by the WorldHealth Organization (WHO). WHO is not responsible for the content or accuracy of this translation. Theoriginal English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with themediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/). Suggested citation.WHO recommendations on the management of sickle cell disease during pregnancy,childbirth and the interpregnancy period. Geneva: World Health Organization; 2025.Licence:CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.CIP data are available athttps://iris.who.int/. Sales, rights and licensing.To purchase WHO publications, seehttps://www.who.int/publications/book-orders. To submit requests for commercial use and queries on rights and licensing, seehttps://www.who.int/copyright. Third-party materials.If you wish to reuse material from this work that is attributed to a third party,such as tables, figures or images, it is your responsibility to determine whether permission is neededfor that reuse and to obtain permission from the copyright holder. The risk of claims resulting frominfringement of any third-party-owned component in the work rests solely with the user. General disclaimers.The designations employed and the presentation of the material in thispublication do not imply the expression of any opinion whatsoever on the part of WHO concerning thelegal status of any country, territory, city or area or of its authorities, or concerning the delimitation of itsfrontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for whichthere may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they areendorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errorsand omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in thispublication. However, the published material is being distributed without warranty of any kind, eitherexpressed or implied. The responsibility for the interpretation and use of the material lies with the reader.In no event shall WHO be liable for damages arising from its use. Cover photo:Sickle-cell disease red blood cells in motion. Freepik AI Image Generator. Contents IntroductionviiiTarget audienceixGuideline development methodsixConsiderations underpinning the recommendationsxRecommendationsxii 1Introduction1 1.1Background11.2Rationale and objectives21.3Target audience21.4Scope of the recommendations31.5Persons affected by the recommendations3 2Methods 2.1Contributors to the guideline42.2Evidence identification and retrieval62.3Quality assessment and grading of the evidence72.4Formulation of the recommendations82.5Management of declaration of interests92.6Decision making during the GDG meetings102.7Document preparation and peer review10 3Recommendations and supporting evidence113.1Recommendations11 4Dissemination and implementation of the guideline35 4.1Dissemination and evaluation354.2Implementation considerations364.3Anticipated impact on the organization of care and resources374.4Monitoring and evaluating guideline implementation38 5Research implications39 Annex 3. Summary and management of declared interests from GDG members47Web Annex,https://doi.org/10.2471/B0941651White paper,https://who.canto.global/b/LIVKQ51 References52 Acknowledgements The Department of Sexual and Reproductive Health and Research and the Department of Maternal, Newborn,Child and Adolescent Health, World Health Organization (WHO) gratefully acknowledge the contributionsof many i